Improved Survival Benefit With the Use of Circulating Tumor Count Application in First-Line Metastatic Breast CancerDecember 9th 2022
Results from the phase 3 STIC CTC trial found an improved overall survival when circulating tumor cells were used as a guide in combination with chemotherapy or endocrine therapy in patients with hormone receptor–positive/HER2-negative breast cancer.
Eribulin Yields Similar Benefit to Standard Chemotherapeutics for HER2-low and HER2-0 Metastatic Breast CancerDecember 8th 2022
Patients with HER2-low or HER2-0 metastatic breast cancer who previously received at least 1 chemotherapy agent garnered similar benefit from eribulin mesylate vs standard physician's choice chemotherapies.
Blood-Based Tumor Mutational Burden Does Not Predict Benefit of Atezolizumab for NSCLCSeptember 21st 2021
According to results from the Blood First Assay Screening Trial, blood-based tumor mutational burden did not predict a benefit of atezolizumab over chemotherapy for patients with non-small cell lung cancer.
Mobocertinib Demonstrates Clinically Meaningful Activity Compared With Real-World Data in Advanced EGFR Exon 20 Insertion+ NSCLCSeptember 16th 2021
For patients with advanced EGFR Exon 20 Insertion–positive non–small cell lung cancer, mobocertinib appears to yield clinically meaningful activity compared with real-world data.
Limited Clinical Activity Attributed to Second-Line Treatment With Linagliptin Plus Atezolizumab in Gastric/GEJ CarcinomaSeptember 16th 2021
Findings from the phase 1b/2 MORPHEUS study indicated that patients with gastric and gastroesophageal junction cancer experienced limited responses to second-line linagliptin plus atezlolizumab.
Radical Prostatectomy as Primary Treatment for Prostate Cancer Leads to Better SurvivalJune 16th 2020
Results presented at the American Urological Association 2020 Virtual Meeting demonstrated that of men who received prior RT or surgery for localized prostate cancer, those that had RT were found to have a 32% higher risk of developing castrate-resistant disease.